GO
Loading...

Bristol-Myers Squibb Co

More

  • Cramer: Best-of-breed stock picks circle back Thursday, 30 Oct 2014 | 6:35 PM ET
    A Chipotle Mexican Grill restaurant is shown in New York.

    Jim Cramer announces his best-of-breed stock picks. Those that will always circle back, because success is a part of their DNA.

  • Midday movers: BorgWarner, Kellogg & more Thursday, 30 Oct 2014 | 12:15 PM ET

    Some of Thursday's midday movers:

  • Oct 28- U.S. Food and Drug Administration staff reviewers recommended approval of a 60 mg dose of Daiichi Sankyo Co's blood thinner for some atrial fibrillation patients, but suggested limiting its use to those with abnormal kidney function. The drug, edoxaban, is a once-daily anticoagulant that inhibits Factor Xa, a protein that plays a central role in...

  • Oct 24- Bristol-Myers Squibb Co reported better-than-expected third-quarter results, as sizzling sales of its treatments for blood clots, cancer and arthritis helped offset sharply higher taxes. That compared with $692 million, or 42 cents per share, in the year-earlier period. Bristol-Myers, along with Merck& Co Inc, Roche Holding AG and AstraZeneca Plc are...

  • Early Movers: F, PG, UPS, AMZN, MSFT Friday, 24 Oct 2014 | 8:44 AM ET

    Some of the names on the move ahead of the open.

  • Oct 24- Bristol-Myers Squibb Co reported better-than-expected third-quarter results, fueled by strong sales of its treatments for blood clots, cancer and arthritis. That compared with $692 million, or 42 cents per share, in the year-earlier period. Revenue fell 4 percent to $3.92 billion, largely due to the company's earlier divestiture of diabetes products,...

  • Market on track for strong week; wary of Ebola news Thursday, 23 Oct 2014 | 7:02 PM ET
    Traders work on the floor of the New York Stock Exchange.

    Stocks head into Friday on track for the best weekly performance in 22 months, yet new Ebola fears and other geopolitical headlines could be wild cards.

  • Cramer: Tune in for the most vital earnings week Friday, 17 Oct 2014 | 6:14 PM ET

    Jim Cramer said next week is the most important week of the year for earnings. Find out what stocks he will be focused on.

  • The first, Esbriet, was developed by InterMune Inc, which Switzerland- based Roche Holding AG agreed to buy for $8.3 billion in August, banking largely on the treatment's potential. The agency's decision marks a crucial milestone in the management of the disease, which affects about 100,000 people in the United States. Roche's drug, known generically as...

  • ConvaTec owners appoint banks to explore sale - sources Wednesday, 15 Oct 2014 | 6:17 AM ET

    LONDON, Oct 15- ConvaTec's owners have appointed Morgan Stanley and Goldman Sachs to explore a sale of the medical device maker which could be worth up to $10 billion, sources familiar with the matter said. Private equity firms Avista Capital Partners and Nordic Capital are preparing the groundwork for a possible sale or initial public offering in 2015 for the...

  • Oct 10- U.S. regulators on Friday approved a new hepatitis C pill from Gilead Sciences Inc, which said it will charge $94,500 for an improved 12- week course of treatment to rid patients of the liver-destroying viral infection. "Unfortunately, we believe that the price being demanded is still inappropriately high for a product targeting such a large group of...

  • Cramer: Activists are picking on the wrong chiefs Thursday, 9 Oct 2014 | 6:25 PM ET
    Jim Cramer on Mad Money.

    Jim Cramer takes on activist calls to CEOs strong performing companies, and suggests they realign their attention

  • Midday movers: Allergan, Deere, GoPro & More Tuesday, 7 Oct 2014 | 1:00 PM ET

    Some of Tuesday's midday movers:

  • NEW YORK, Oct 7- Bristol-Myers Squibb Co on Tuesday said it is no longer seeking U.S. approval for an oral two-drug combination to treat hepatitis C because of competition from rival drugs that require treatment for half as long and have shown higher cure rates. In addition, Bristol-Myers' drug faced stiff competition from products being developed by rival...

  • Oct 7- Bristol-Myers Squibb said it withdrew its U.S. marketing application for an oral drug combination to treat hepatitis C, citing a "rapidly evolving" treatment landscape in the country. Bristol-Myers is racing against Merck& Co and AbbVie to try and cut the treatment time by half and avoid side effects from older standard drugs interferon and ribavirin.

  • Oct 7- Bristol-Myers Squibb said it withdrew its U.S. marketing application for a drug combination to treat hepatitis C. Bristol-Myers said the combination treatment of daclatasvir and asunaprevir was approved in July for use in Japan. The company plans to submit additional data on daclatasvir from an ongoing study to the U.S. Food and Drug Administration.

  • LONDON, Oct 6- AstraZeneca's blood-thinning drug Brilinta has won preferred status in the United States, where two medical groups have recommended it over the older drug Plavix, also known as clopidogrel. AstraZeneca said on Monday it was the first time the cardiology organizations had recommended one drug of this type over another in the treatment of acute...

  • Oct 1- Portola Pharmaceuticals Inc said its drug met the main goal of reversing the effect of anti-coagulant drugs in a late-stage study. Data showed that an intravenous shot of the drug, andexanet alfa, immediately reversed the effect of Eliquis, an anti-clotting drug by Bristol-Myers Squibb Co and Pfizer Inc..

  • MADRID, Sept 30- A raft of new cancer drugs promise better, longer-lasting treatments with fewer adverse side effects-- but their high cost is a growing concern. Price-- just as much as safety and efficacy-- has proved a hot topic for nearly 20,000 oncology experts at the European Society for Medical Oncology annual congress in Madrid.

  • Cancer drug stocks on the move amid striking data Monday, 29 Sep 2014 | 11:14 AM ET

    Data released at the European Society of Medical Oncology meeting over the weekend showed much progress in fighting a number of cancers. Here's what investors need to know.